BD recently received CE Marking for the Liverty™ TIPS Stent Graft, a next-generation, adjustable-diameter device designed to expand treatment options for patients with cirrhosis and complications of portal hypertension. Safety and effectiveness data from the pivotal ARCH clinical trial were first presented on podium by Global Principal Investigator Prof. Ziv Haskal, MD, at SIR on April 12, 2026.

At RÖKO Leipzig, the ARCH trial data will be presented on podium, marking a key milestone in the European launch of Liverty™. The ARCH trial provides the first and only prospective data describing the results of small-diameter calibrated TIPS for treating all major complications of portal hypertension. This presentation brings the pivotal dataset to the European interventional radiology community for the first time, positioning Liverty™ as a meaningful advancement in individualized portal hypertension care.

Please join us on Thursday, May 14, in Saal 5 from 4:30 p.m. to 5:30 p.m. for our Late-Breaking Abstract on TIPS Stent.